NICE Onpattro approval puts Alnylam back in hATTR running
NICE issued the drug a preliminary ‘no’, back in December 2018.
Read Moreby Anna Smith | Jul 9, 2019 | News | 0
NICE issued the drug a preliminary ‘no’, back in December 2018.
Read Moreby Selina McKee | Dec 12, 2018 | News | 0
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
Read Moreby Selina McKee | Aug 31, 2018 | News | 0
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.
Read Moreby Selina McKee | Aug 13, 2018 | News | 0
The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Read Moreby Selina McKee | Sep 21, 2017 | News | 0
An investigational RNAi therapeutic being developed by Sanofi Genzyme and Alnylam Pharmaceuticals has hit targets in a late stage trial involving patients with hereditary ATTR amyloidosis with polyneuropathy.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
